T2* Mapping from Multi-Echo Dixon Sequence on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for the Hepatic Fat Quantification: Can It Be Used for Hepatic Function Assessment?

다국어 초록 (Multilingual Abstract)

Objective: To evaluate the diagnostic value of T2* mapping using 3D multi-echo Dixon gradient echo acquisition on gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) as a tool to evaluate hepatic function.
Materials and Methods: This retrospective study was approved by the IRB and the requirement of informed consent was waived. 242 patients who underwent liver MRIs, including 3D multi-echo Dixon fast gradient-recalled echo (GRE) sequence at 3T, before and after administration of gadoxetic acid, were included. Based on clinico-laboratory manifestation, the patients were classified as having normal liver function (NLF, n = 50), mild liver damage (MLD, n = 143), or severe liver damage (SLD, n = 30). The 3D multi-echo Dixon GRE sequence was obtained before, and 10 minutes after, gadoxetic acid administration. Pre- and post-contrast T2* values, as well as T2* reduction rates, were measured from T2* maps, and compared among the three groups.
Results: There was a significant difference in T2* reduction rates between the NLF and SLD groups (-0.2 ± 4.9% vs. 5.0 ± 6.9%, p = 0.002), and between the MLD and SLD groups (3.2 ± 6.0% vs. 5.0 ± 6.9%, p = 0.003). However, there was no significant difference in both the pre- and post-contrast T2* values among different liver function groups (p = 0.735 and 0.131, respectively). A receiver operating characteristic (ROC) curve analysis showed that the area under the ROC curve for using T2* reduction rates to differentiate the SLD group from the NLF group was 0.74 (95% confidence interval: 0.63–0.83).
Conclusion: Incorporation of T2* mapping using 3D multi-echo Dixon GRE sequence in gadoxetic acid-enhanced liver MRI protocol may provide supplemental information for liver function deterioration in patients with SLD.

참고문헌 (Reference)

1 Kudo M, "Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma?" 78 (78): 87-93, 2010

2 Haimerl M, "Volume-assisted estimation of liver function based on Gd-EOB-DTPA-enhanced MR relaxometry" 26 : 1125-1133, 2016

3 Ding Y, "Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease" 24 : 959-966, 2014

4 Hines CD, "T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis" 33 : 873-881, 2011

5 Dinant S, "Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry" 48 : 685-692, 2007

6 Storey P, "R2* imaging of transfusional iron burden at 3T and comparison with 1.5T" 25 : 540-547, 2007

7 Bannas P, "Quantitative magnetic resonance imaging of hepatic steatosis: validation in ex vivo human livers" 62 : 1444-1455, 2015

8 Kamimura K, "Quantitative evaluation of liver function with T1 relaxation time index on Gd-EOB-DTPA-enhanced MRI:comparison with signal intensity-based indices" 40 : 884-889, 2014

9 Yoon JH, "Quantitative assessment of hepatic function: modified look-locker inversion recovery (MOLLI) sequence for T1 mapping on Gd-EOB-DTPAenhanced liver MR imaging" 26 : 1775-1782, 2016

10 Alústiza Echeverría JM, "Quantification of iron concentration in the liver by MRI" 3 : 173-180, 2012

11 Meisamy S, "Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy" 258 : 767-775, 2011

12 Kwon AH, "Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (99mTc-GSA) liver scintigraphy" 25 : 426-429, 1997

13 Tsuda N, "Potential of gadoliniumethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging" 42 : 242-247, 2007

14 Stikov N, "On the accuracy of T1 mapping: searching for common ground" 73 : 514-522, 2015

15 윤정희, "Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues" 대한영상의학회 17 (17): 7-24, 2016

16 Matteoni CA, "Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity" 116 : 1413-1419, 1999

17 Tang A, "Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis" 267 : 422-431, 2013

18 Yu H, "Multiecho reconstruction for simultaneous water-fat decomposition and T2* estimation" 26 : 1153-1161, 2007

19 Dietrich CG, "Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance" 22 : 72-88, 2016

20 Chang ML, "Metabolic alterations and hepatitis C: from bench to bedside" 22 : 1461-1476, 2016

21 Bruix J, "Management of hepatocellular carcinoma: an update" 53 : 1020-1022, 2011

22 Garcia-Tsao G, "Management and treatment of patients with cirrhosis and portal hypertension:recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program" 104 : 1802-1829, 2009

23 Haimerl M, "MRI-based estimation of liver function: Gd-EOBDTPA-enhanced T1 relaxometry of 3T vs. the MELD score" 4 : 5621-, 2014

24 Cassinotto C, "MR relaxometry in chronic liver diseases:comparison of T1 mapping, T2 mapping, and diffusionweighted imaging for assessing cirrhosis diagnosis and severity" 84 : 1459-1465, 2015

25 Motosugi U, "Liver parenchymal enhancement of hepatocytephase images in Gd-EOB-DTPA-enhanced MR imaging:which biological markers of the liver function affect the enhancement?" 30 : 1042-1046, 2009

26 Friedman SL, "Liver fibrosis--from bench to bedside" 38 (38): S38-S53, 2003

27 Lee YJ, "Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis" 275 : 97-109, 2015

28 Frydrychowicz A, "Hepatobiliary MR imaging with gadoliniumbased contrast agents" 35 : 492-511, 2012

29 Nilsson H, "Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis" 86 : 20120653-, 2013

30 Schmitz SA, "Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats" 31 : 154-160, 1996

31 Shimizu J, "Evaluation of regional liver function by gadolinium-EOBDTPA-enhanced MR imaging" 44 : 1330-1337, 1999

32 Fan ST, "Evaluation of indocyanine green retention and aminopyrine breath tests in patients with malignant biliary obstruction" 64 : 759-762, 1994

33 Katsube T, "Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging" 81 : 1460-1464, 2012

34 Hernando D, "Effect of hepatocyte-specific gadolinium-based contrast agents on hepatic fat-fraction and R2(*)" 33 : 43-50, 2015

35 Eggers H, "Dual-echo Dixon imaging with flexible choice of echo times" 65 : 96-107, 2011

36 Kukuk GM, "Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis" 25 : 2869-2879, 2015

37 Starr SP, "Cirrhosis: diagnosis, management, and prevention" 84 : 1353-1359, 2011

38 Heidelbaugh JJ, "Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation" 74 : 756-762, 2006

39 Park BJ, "Chronic liver inflammation:clinical implications beyond alcoholic liver disease" 20 : 2168-2175, 2014

40 Kim JY, "Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents" 201 : 322-331, 2013

41 Bae KE, "Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI" 30 : 617-622, 2012

42 Inoue T, "Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT" 47 : 1036-1047, 2012

43 Ge PL, "Advances in preoperative assessment of liver function" 13 : 361-370, 2014

44 Ahn SS, "Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma" 255 : 459-466, 2010

45 Besa C, "3D T1relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function" 33 : 1075-1082, 2015

46 Korean Liver Cancer Study Group, "2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma" 대한영상의학회 16 (16): 465-522, 2015

47 de Graaf W, "(99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy" 51 : 229-236, 2010